Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The problem with potency

Industry hopes to build on recent successes of monoclonal antibodies in oncology and inflammatory disease. But evidence is mounting that the exquisite selectivity and binding capacity of these therapeutics can have unwanted side effects, particularly in autoimmune disease. Christopher Thomas Scott investigates.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Berger, J.R. & Koralnik, I.J. N. Engl. J. Med. 353, 414–416 (2005).

    Article  CAS  Google Scholar 

  2. Sheridan, C. Nat. Rev. Drug Discov. 4, 357–358 (2005).

    Article  CAS  Google Scholar 

  3. Ozcelik, C. et al. Proc. Natl. Acad. Sci. USA 99, 8880–8885 (2002).

    Article  CAS  Google Scholar 

  4. Phan, G.Q. et al. Proc. Natl. Acad. Sci. USA 100, 8372–8377 (2003).

    Article  CAS  Google Scholar 

  5. Steinman, L. Nat. Rev. Drug Discov., 4, 510–519 (2005).

    Article  CAS  Google Scholar 

  6. Yednock, T. et al. Nature 356, 63–66 (1992)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Scott, C. The problem with potency. Nat Biotechnol 23, 1037–1039 (2005).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing